Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02582697 · ClinicalTrials.gov registry record · Phase 3
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
A Phase 3 study of Germ Cell Tumor, sponsored by University of Sydney.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT02582697: Recruiting Phase 3 study of Germ Cell Tumor, sponsored by University of Sydney.
NCT02582697 is a Phase 3 study of Germ Cell Tumor that is actively recruiting participants, run by University of Sydney. The registered enrollment target is 500 participants, above the 321-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02582697, a Phase 3 study of Germ Cell Tumor, is actively recruiting participants, sponsored by University of Sydney.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Primary Outcome
PFS is measured from the date of randomisation until the criteria for disease progression are met (as defined in the protocol) or death. Participants who are not observed to progress nor die will be censored at the date of last follow-up
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Filgrastim
- DRUG Bleomycin (active name: Bleomycin Sulfate)
- DRUG Pegylated G-CSF (Pegfilgrastim)
Study Locations (20)
New South Wales
- Calvary Mater Newcastle - Newcastle
- Royal North Shore Hospital - St Leonards
- Prince of Wales Hospital - Sydney
- Chris O'Brien Lifehouse - Sydney
- Macquarie Cancer Clinical Trials - Sydney
- Concord Repatriation General Hospital - Sydney
- Westmead Hospital - Sydney
- Nepean Hospital - Sydney
- Tweed Hospital - Tweed Heads
- SAN Clinical Trials Unit - Wahroonga
Queensland
- Royal Brisbane & Women's Hospital - Brisbane
- Queensland Children's Hospital - South Brisbane
- Princess Alexandra - Woolloongabba
Victoria
- Box Hill Hospital - Box Hill
- Peter MacCallum Cancer Centre - East Melbourne
- Austin Health - Heidelberg
South Australia
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford Park
New York
- Memorial Sloan Kettering Cancer Centre - New York
Tasmania
- Royal Hobart Hospital - Hobart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-02 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
What NCT02582697 shows while recruiting
NCT02582697 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 321-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (56% higher).
The record links to 1 condition, with Germ Cell Tumor appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT02582697 names 20 study sites across 6 states, led by New South Wales, Queensland, Victoria.
Frequently Asked Questions
What is clinical trial NCT02582697 about?
NCT02582697 is a clinical study titled "Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours". The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
What is the current status of trial NCT02582697?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2014-02. Estimated completion is 2029-12-31.
What conditions does trial NCT02582697 study?
This clinical trial studies the following conditions: Germ Cell Tumor.
What interventions are being tested in trial NCT02582697?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Filgrastim (DRUG), Bleomycin (active name: Bleomycin Sulfate) (DRUG), Pegylated G-CSF (Pegfilgrastim) (DRUG).
Who is sponsoring clinical trial NCT02582697?
This trial is sponsored by University of Sydney, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02582697 being conducted?
This trial has 20 study locations across New York, New South Wales, Queensland, South Australia, Tasmania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02582697's enrollment target sits among peer trials
500 5th of 19 higher than 15 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia